14.08

2.29% -0.33

After Hours: 14.00 -0.08 -0.57%

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $14.08, with a volume of 7.59M. It is down -2.29% in the last 24 hours and up +21.69% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$14.41

Open:

$14.4

24h Volume:

7.59M

Relative Volume:

1.22

Market Cap:

$9.61B

Revenue:

$125.68M

Net Income/Loss:

$4.81B

P/E Ratio:

2.492

EPS:

5.65

Net Cash Flow:

$-781.21M

1W Performance:

+8.98%

1M Performance:

+21.69%

6M Performance:

+32.83%

1Y Performance:

+16.17%

1-Day Range:

$14.07

$14.47

1-Week Range:

$12.54

$14.47

52-Week Range:

$8.73

$14.47

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

750

Twitter

Next Earnings Date

2025-02-10

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	14.08	9.40B	125.68M	4.81B	-781.21M	5.65
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Sep 12, 2025

Two Seas Capital LP Sells 31,500 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat

Sep 12, 2025

Roivant Sciences (ROIV) Announces US$500 Million Share Repurchase Program Amid Recent Challenges - simplywall.st

Sep 12, 2025

Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month HighStill a Buy? - MarketBeat

Sep 12, 2025

Teza Capital Management LLC Buys New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat

Sep 12, 2025

Sep 11, 2025